English
Home > Products > CAS NO:171596-29-5

China CAS NO:171596-29-5 Factory

continue to enhance, to be certain solution top quality in line with market and buyer standard requirements. Our corporation has a excellent assurance program are actually established for CAS NO:171596-29-5,Tadalafil API,Tadalafil, We are looking forwards to establishing long-term business relationships with worldwide customers.
CAS NO:171596-29-5, To get more information about us as well as see all our products and solutions, you should visit our website. To get more information please feel free to let us know. Thank you very much and wish your business always be great!

Related Products

Hot Products

  • Ranitidine hydrochloride

    Ranitidine hydrochloride

    Product Name:Ranitidine hydrochloride
    Molecular Formula:C13H23ClN4O3S
    Molecular Weight:350.86
    CAS Registry Number:71130-06-8
  • Ethyltriphenylphosphonium bromide

    Ethyltriphenylphosphonium bromide

    Product Name:Ethyltriphenylphosphonium bromide
    Molecular Formula:C20H20BrP
    Molecular Weight:371.25
    CAS Registry Number:1530-32-1
  • 4-Bromomethyl-2-cyanobiphenyl

    4-Bromomethyl-2-cyanobiphenyl

    Product Name:4-Bromomethyl-2-cyanobiphenyl
    Molecular Formula:C14H10BrN
    Molecular Weight:272.14
    CAS Registry Number:114772-54-2
  • 3-Pyrrolidinepropanamide, α-amino-2-oxo-, hydrochloride

    3-Pyrrolidinepropanamide, α-amino-2-oxo-, hydrochloride

    Product Name:3-Pyrrolidinepropanamide, α-amino-2-oxo-, hydrochloride
    Molecular Formula:C7H14ClN3O2
    Molecular Weight:207.66
    CAS Registry Number:2628280-48-6
  • Acrivastine

    Acrivastine

    Product Name:Acrivastine
    Molecular Formula:C22H24N2O2
    Molecular Weight;348.44
    CAS Registry Number;87848-99-5
  • Puerarin

    Puerarin

    Product Name:Puerarin
    Molecular Formula:C21H20O9
    Molecular Weight:416.38
    CAS Registry Number:3681-99-0
  • Related Blog
  • Reviews

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept